These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 29651)

  • 1. Metabolism of lergotrile to 13-hydroxy lergotrile, a potent inhibitor of prolactin release in vitro.
    Parli CJ; Schmidt B; Shaar CJ
    Biochem Pharmacol; 1978 May; 27(9):1405-8. PubMed ID: 29651
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of dopamine, bromocriptine, lergotrile and metoclopramide on prolactin release from continuously perfused columns of isolated rat pituitary cells.
    Yeo T; Thorner MO; Jones A; Lowry PJ; Besser GM
    Clin Endocrinol (Oxf); 1979 Feb; 10(2):123-30. PubMed ID: 34491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of the dopamine agonist, lergotrile mesylate, on prolactin secretion in women.
    Leebaw W; Lee L; Woolf P
    Acta Endocrinol (Copenh); 1978 Jan; 87(1):12-8. PubMed ID: 579527
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of 2-bromo-alpha-ergocryptine and 2-chloro-alpha-methylergoline-8beta-acetonitrile (lergotrile mesylate) on the prolactin secretion of the ewe.
    Hooley RD; Fell LR; Findlay JK
    Acta Endocrinol (Copenh); 1977 Dec; 86(4):722-7. PubMed ID: 411304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of prolactin secretion by lergotrile mesylate: mechanism of action.
    Clemens JA; Smalstig EB; Shaar CJ
    Acta Endocrinol (Copenh); 1975 Jun; 79(2):230-7. PubMed ID: 166535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible involvement of dopamine in the release of prolactin-like hormone from bullfrog pituitary gland.
    Kikuyama S; Seki T
    Gen Comp Endocrinol; 1980 Jun; 41(2):173-9. PubMed ID: 6968286
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of oestrogen and bromocryptine on in vivo secretion and mitosis in prolactin cells.
    Lloyd HM; Meares JD; Jacobi J
    Nature; 1975 Jun; 255(5508):497-8. PubMed ID: 1138203
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of ergoline derivative VUFB-6638 on the adenohypophysial prolactin concentration in rats.
    Krejcí P; Ausková M; Rezábek K; Bílek J; Semonský M
    Endocrinol Exp; 1975 Jan; 9(1):68-72. PubMed ID: 6259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lisuride, a dopamine agonist, inhibits DNA synthesis in the pituitary gland.
    Burdman JA; Calabrese MT; Harcus CT; MacLeod RM
    Neuroendocrinology; 1982 Oct; 35(4):282-6. PubMed ID: 7145022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolactin binding to R3230AC mammary carcinoma and liver in hormone-treated and diabetic rats.
    Smith RD; Hilf R; Senior AE
    Cancer Res; 1977 Feb; 37(2):595-8. PubMed ID: 188551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of lergotrile mesylate and methysergide on morphine induced increase in prolactin release.
    Ratner A; Woo W; Yelvington D; Torres K
    Proc West Pharmacol Soc; 1981; 24():335-9. PubMed ID: 6114495
    [No Abstract]   [Full Text] [Related]  

  • 12. Changes in the concentration of adenohypophyseal prolactin and morphological manifestations in the adenohypophysis of lactating rats after administration of D-6-methyl-8-[beta-isopropylaminoethyl] ergoline-I.
    Krejcí P; Marhan O; Ausková M; Rezábek K; Semonský M
    Experientia; 1976 Oct; 32(10):1308-9. PubMed ID: 987925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulation of prolactin release by vasoactive intestinal peptide (VIP).
    Ruberg M; Rotsztejn WH; Arancibia S; Besson J; Enjalbert A
    Eur J Pharmacol; 1978 Oct; 51(3):319-20. PubMed ID: 710507
    [No Abstract]   [Full Text] [Related]  

  • 14. Pergolide mesylate inhibits exercise-induced prolactin release in man.
    De Meirleir K; Baeyens L; L'Hermite M; L'Hermite-Balériaux M; Olbrecht J; Holmann W
    Fertil Steril; 1985 Apr; 43(4):628-31. PubMed ID: 3987929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the effects of CB-154 and lergotrile mesylate on prolactin and growth hormone secretion in mice.
    Sinha YN; Salocks CB; VanderLaan WP
    Horm Metab Res; 1976 Sep; 8(5):332-6. PubMed ID: 989755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metergoline and cyproheptadine suppress prolactin release by a non-5-hydroxytryptaminergic, non-dopaminergic mechanism.
    Besser GM; Delitala G; Grossman A; Yeo T
    Br J Pharmacol; 1980 Sep; 70(1):5-7. PubMed ID: 7426830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactin binding to mammary gland, 7,12-dimethylbenz(a)-anthracene-induced mammary tumors, and liver in rats.
    Smith RD; Hilf R; Senior AE
    Cancer Res; 1976 Oct; 36(10):3726-31. PubMed ID: 821605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of calcitonin on prolactin release in rats.
    Iwasaki Y; Chihara K; Iwasaki J; Abe H; Fujita T
    Life Sci; 1979 Oct; 25(14):1243-8. PubMed ID: 513955
    [No Abstract]   [Full Text] [Related]  

  • 19. Physiologic disposition of lergotrile.
    Rubin A; Lemberger L; Dhahir P; Warrick P; Crabtree RE; Obermeyer BD; Wolen RL; Rowe H
    Clin Pharmacol Ther; 1978 Mar; 23(3):272-80. PubMed ID: 627132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent antidopaminergic activity of estradiol at the pituitary level on prolactin release.
    Raymond V; Beaulieu M; Labrie F; Boissier J
    Science; 1978 Jun; 200(4346):1173-5. PubMed ID: 418505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.